ARCTURUS THERAPEUTICS HOLDINGS INC. Financing Cash Flow
ARCTURUS THERAPEUTICS HOLDINGS INC. (ARCT) reported Financing Cash Flow of $16.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $0.00.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $16.00K, a 99.89% decline year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $11.69M, a 8622.39% increase year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.23M, a 76.77% increase year-over-year.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) financing activities for fiscal 2025 was $13.38M, a 146.99% increase from fiscal 2024.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) financing activities for fiscal 2024 was $5.42M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) financing activities for fiscal 2023 was -$24.09M.
- ARCTURUS THERAPEUTICS HOLDINGS INC. net cash provided by (used in) financing activities for fiscal 2022 was -$2.86M, a 105.95% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $16.00K 10-Q · filed 2026-08-06 | $11.70M derived: sum of 3 quarters · filed 2026-08-06 | $12.93M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $16.00K 10-Q · filed 2026-05-07 | $11.70M derived: sum of 2 quarters · filed 2026-05-07 | $12.93M derived: sum of 3 quarters · filed 2026-05-07 | -$1.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $11.69M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $12.91M derived: sum of 2 quarters · filed 2026-03-03 | -$1.81M derived: sum of 3 quarters · filed 2026-08-06 | $13.38M 10-K · filed 2026-03-03 |
| 2025-09-30 | $1.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$13.50M derived: sum of 2 quarters · filed 2026-08-06 | $1.69M 10-Q · filed 2025-11-12 | $1.83M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$14.73M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $469.00K 10-Q · filed 2026-08-06 | $603.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $15.20M 10-Q · filed 2026-05-07 | $15.33M derived: sum of 2 quarters · filed 2026-05-07 | $16.02M derived: sum of 3 quarters · filed 2026-05-07 | $18.43M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $134.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $827.00K derived: sum of 2 quarters · filed 2026-03-03 | $3.23M derived: sum of 3 quarters · filed 2026-03-03 | $5.42M 10-K · filed 2026-03-03 |
| 2024-09-30 | $693.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $3.10M derived: sum of 2 quarters · filed 2025-11-12 | $5.28M 10-Q · filed 2025-11-12 | -$13.37M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-06-30 | $2.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $4.59M 10-Q · filed 2025-08-11 | -$14.07M derived: sum of 3 quarters · filed 2026-03-03 | $7.77M derived: sum of 4 quarters · filed 2026-03-03 |
| 2024-03-31 | $2.19M 10-Q · filed 2025-05-12 | -$16.47M derived: sum of 2 quarters · filed 2026-03-03 | $5.37M derived: sum of 3 quarters · filed 2026-03-03 | $5.46M derived: sum of 4 quarters · filed 2026-03-03 |
| 2023-12-31 | -$18.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $3.18M derived: sum of 2 quarters · filed 2026-03-03 | $3.28M derived: sum of 3 quarters · filed 2026-03-03 | -$24.09M 10-K · filed 2026-03-03 |
| 2023-09-30 | $21.84M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $21.93M derived: sum of 2 quarters · filed 2024-11-07 | -$5.43M 10-Q · filed 2024-11-07 | -$7.66M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $94.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | -$27.27M 10-Q · filed 2024-08-05 | -$29.50M derived: sum of 3 quarters · filed 2025-03-06 | -$30.72M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | -$27.36M 10-Q · filed 2024-05-08 | -$29.60M derived: sum of 2 quarters · filed 2025-03-06 | -$30.82M derived: sum of 3 quarters · filed 2025-03-06 | -$30.56M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | -$2.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | -$3.45M derived: sum of 2 quarters · filed 2025-03-06 | -$3.19M derived: sum of 3 quarters · filed 2025-03-06 | -$2.86M 10-K · filed 2025-03-06 |
| 2022-09-30 | -$1.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$963.00K derived: sum of 2 quarters · filed 2023-11-14 | -$627.00K 10-Q · filed 2023-11-14 | -$397.00K derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-06-30 | $257.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $593.00K 10-Q · filed 2023-08-07 | $823.00K derived: sum of 3 quarters · filed 2024-03-14 | $1.51M derived: sum of 4 quarters · filed 2024-03-14 |
| 2022-03-31 | $336.00K 10-Q · filed 2023-05-09 | $566.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.26M derived: sum of 3 quarters · filed 2024-03-14 | $1.34M derived: sum of 4 quarters · filed 2024-03-14 |
| 2021-12-31 | $230.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $922.00K derived: sum of 2 quarters · filed 2024-03-14 | $1.00M derived: sum of 3 quarters · filed 2024-03-14 | $48.02M 10-K · filed 2024-03-14 |
| 2021-09-30 | $692.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $774.00K derived: sum of 2 quarters · filed 2022-11-09 | $47.79M 10-Q · filed 2022-11-09 | $210.99M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $82.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $47.09M 10-Q · filed 2022-08-09 | $210.29M derived: sum of 3 quarters · filed 2022-08-09 | $397.52M derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $47.01M 10-Q · filed 2022-05-09 | $210.21M derived: sum of 2 quarters · filed 2022-05-09 | $397.44M derived: sum of 3 quarters · filed 2022-05-09 | $483.04M derived: sum of 4 quarters · filed 2022-05-09 |
| 2020-12-31 | $163.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $350.42M derived: sum of 2 quarters · filed 2022-03-01 | $436.03M derived: sum of 3 quarters · filed 2022-03-01 | $436.14M 10-K · filed 2022-03-01 |
| 2020-09-30 | $187.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $272.83M derived: sum of 2 quarters · filed 2021-11-09 | $272.94M 10-Q · filed 2021-11-09 | $277.98M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $85.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-10 | $85.72M 10-Q · filed 2021-08-10 | $90.75M derived: sum of 3 quarters · filed 2022-03-01 | $112.08M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $118.00K 10-Q · filed 2021-05-10 | $5.15M derived: sum of 2 quarters · filed 2022-03-01 | $26.48M derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $5.03M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $26.36M derived: sum of 2 quarters · filed 2022-03-01 | $41.91M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $21.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $36.87M 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | $15.55M 10-Q · filed 2020-08-10 | |||
| 2018-12-31 | $9.87M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $9.85M derived: sum of 2 quarters · filed 2021-03-01 | $10.20M 10-K · filed 2021-03-01 | |
| 2018-09-30 | -$19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $332.00K 10-Q · filed 2019-11-08 | ||
| 2018-06-30 | $351.00K 10-Q · filed 2019-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |